Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23.
Verona Pharma Plc (VRNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 6,317,990 | $125,601,641 | 1.96% | |
| 2. | Vivo Capital Albert Cha And Frank Kung | 4,249,918 | $84,488,370 | 6.91% | |
| 3. | Perceptive Advisors Joseph Edelman | 3,866,214 | $76,860,334 | -4% | 1.71% |
| 4. | OrbiMed Advisors Samuel Isaly | 3,777,778 | $75,102,227 | 1.49% | |
| 5. | Deep Track Capital David Kroin | 3,187,415 | $63,365,810 | 2.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.84 | 33,736 | Director | 144,800 | 2023-11-20 | Filing | |
| $1.98 | 160,000 | Director | 844,643 | 2023-11-06 | Filing | |
| $1.31 | 4,800,000 | Large Shareholder | 55,911,648 | 2022-08-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.22 | 36,248 | Officer | 2,731,624 | 2024-02-05 | Filing | |
| $1.92 | 58,752 | Officer | 2,840,640 | 2023-11-03 | Filing | |
| $2.47 | 1,600 | Officer | 2,872,528 | 2023-08-07 | Filing | |
| $2.50 | 27,944 | Officer | 2,874,128 | 2023-08-04 | Filing | |
| $2.54 | 21,848 | Officer | 2,902,072 | 2023-08-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,108,563 | $111,024,890 | 7.39% | |
| 2. | 4,902,377 | $97,459,255 | 0% | |
| 3. | 3,783,994 | $75,225,800 | 0.01% | |
| 4. | 3,014,349 | $59,925,258 | 3.2% | |
| 5. | 2,493,530 | $49,571,376 | 0.12% |
News See All
11 Best Undervalued UK Stocks To Buy Now
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q3 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode.
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now.
Verona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call Transcript
Operator: Welcome to Verona Pharma Second Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time all participants are in listen-only mode.
Verona Pharma plc (NASDAQ:VRNA) Q1 2023 Earnings Call Transcript
Operator: Good morning. Welcome to Verona Pharma's First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode.
Verona Pharma plc (NASDAQ:VRNA) Q4 2022 Earnings Call Transcript
Operator: Welcome to Verona Pharma's, Fourth Quarter and Full Year 2022 Financial Results and Operating Highlights Conference Call. At this time all participants are in a listen-only mode.
12 Best Performing NASDAQ Stocks in 2022
The S&P 500 rose 0.6% to 3,844.82 on December 23, while the Nasdaq Composite gained 0.2% to close at 10,497.86. The Dow Jones Industrial Average also closed 176.44 points or 0.5% higher at 33,203.93.
5 Best Performing Biotech Stocks in 2022
Verona Pharma plc (NASDAQ:VRNA) is a London-based clinical stage biopharmaceutical company, focused on development and commercialization of therapies for the treatment of respiratory diseases with unmet...
Is Verona Pharma plc (VRNA) A Good Stock To Buy?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in...
Billionaire Hedge Funds
